Windsor Joseph W, Kuenzig M Ellen, Murthy Sanjay K, Bitton Alain, Bernstein Charles N, Jones Jennifer L, Lee Kate, Targownik Laura E, Peña-Sánchez Juan-Nicolás, Rohatinsky Noelle, Ghandeharian Sara, Im James H B, Davis Tal, Weinstein Jake, Goddard Quinn, Benchimol Eric I, Kaplan Gilaad G
Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
SickKids Inflammatory Bowel Disease Centre, Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, Ontario, Canada.
J Can Assoc Gastroenterol. 2023 Jun 1;6(Suppl 2):S1-S8. doi: 10.1093/jcag/gwad003. eCollection 2023 Sep.
The burden of inflammatory bowel disease (IBD) (i.e., associated direct and indirect costs, prevalence of disease, personal impact to the individual and to caregivers) continues to increase in Canada. The prevalence of IBD has increased since Crohn's and Colitis Canada's 2018 Impact of IBD report from an estimated 270,000 Canadians living with IBD in 2018 to an estimated 322,600 Canadians living with IBD today in 2023. Consequently, associated costs of IBD have also dramatically increased from an estimated $2.57 billion in 2018 to an estimated $5.38 billion in 2023; this increase is due to multiple factors including increased prevalence of disease, inflation, and additional identified factors (e.g., presenteeism, costs of childcare). Beyond the economic impact of IBD, these diseases have a significant impact on people living with the disease and their caregivers, including different presentations of disease, different commonly associated extra-intestinal manifestations or comorbid conditions, and different barriers to accessing care. In this supplementary issue, we review: Evolving trends in the epidemiology of IBD; updated estimates of indirect and direct costs (including out-of-pocket costs) associated with IBD; information specific to IBD in children, adolescents, and seniors; issues related to IBD pertaining to sex and gender; information specific to risks associated with COVID-19 and cancer related to IBD; an overview of current treatments for IBD; and evolving care models, including access to care.
在加拿大，炎症性肠病（IBD）的负担（即相关的直接和间接成本、疾病患病率、对个人及护理人员的个人影响）持续上升。自加拿大克罗恩病和结肠炎协会发布2018年IBD影响报告以来，IBD的患病率有所增加，从2018年估计约27万加拿大IBD患者增加到2023年估计约32.2万加拿大IBD患者。因此，IBD的相关成本也大幅增加，从2018年估计的25.7亿加元增至2023年估计的53.8亿加元；这种增长归因于多种因素。包括疾病患病率上升、通货膨胀以及其他已确定因素（如带病出勤、育儿成本）。除了IBD的经济影响外，这些疾病对患者及其护理人员有重大影响，包括疾病的不同表现形式、常见的不同肠外表现或合并症，以及获得护理的不同障碍。在本期增刊中，我们回顾了：IBD流行病学的演变趋势；与IBD相关的间接和直接成本（包括自付费用）的最新估计；儿童、青少年和老年人IBD的具体信息；与IBD有关的性别问题；与IBD相关的COVID-19和癌症风险的具体信息；IBD当前治疗方法概述；以及不断发展的护理模式，包括获得护理的情况。
